HCPCS J0585: OnabotulinumtoxinA (Botox) Injection

What is HCPCS J0585 used for?

HCPCS J0585 reports onabotulinumtoxinA — Botox — per 1 unit. It is a botulinum toxin type A used for covered indications including chronic migraine, cervical dystonia, upper- and lower-limb spasticity, blepharospasm, strabismus, and overactive bladder. J0585 bills the drug by the unit; the injection procedure (a chemodenervation CPT such as 64615 for migraine, or 96372 for a simple therapeutic injection) is billed separately.

How do you count units and vials for J0585?

The key rule: one Botox unit = one J0585 billing unit. Botox is supplied in single-use 100-unit and 200-unit vials.

Example: the standard chronic-migraine protocol is 155 units across 31 sites — billed as J0585 x155, with any remainder from the vial reported as waste.

How is J0585 priced, and does it need prior authorization?

As a Medicare Part B separately payable drug, onabotulinumtoxinA is reimbursed at roughly ASP plus 6 percent. The average sales price is published by CMS and updated quarterly, so the per-unit rate changes each quarter — bill the units and let the payer apply the current ASP file. Because Botox is high-cost and indication-specific, many payers require prior authorization and documented medical necessity for the covered diagnosis.

How do JW and JZ modifiers apply to J0585?

Botox vials are single-use, so the discarded-drug rules always apply:

• JW — reports the discarded units on a separate line so Medicare pays for the labeled vial amount.
• JZ — attests there were no discarded units.

One of the two is required on every separately payable single-dose Botox claim. The same ASP-and-waste framework governs the sibling drugs J3301 and J1100. For the payable administration and chemodenervation services, check rates in the Medicare fee calculator under Part B.